- CLARITY-Gastric01: Phase III of Sone-Ve in 2L+ CLDN18.2-positive gastric/GEJ cancer vs investigator's choice. First Phase III to show OS benefit with anti-CLDN18.2 ADC in this setting.
- SAFFRON: Phase III of TAGRISSO plus savolitinib in MET-driven EGFRm NSCLC after progression vs platinum chemo.
- VOLGA: Phase III of perioperative IMFINZI plus neoadjuvant enfortumab vedotin in cisplatin-ineligible muscle-invasive bladder cancer.
- DeLLphi-305: Amgen-led Phase III of IMFINZI plus tarlatamab as 1L maintenance in ES-SCLC vs IMFINZI alone.
- SANOVO: Hutchmed-led Phase III of TAGRISSO plus savolitinib in treatment-naïve MET-overexpressed EGFRm NSCLC in China.
- Over 100 abstracts presented across AstraZeneca portfolio at ESMO 2026.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card 
